文献速递瓣膜病与结构性心脏病

心脏瓣膜中心与基层中心对重度主动脉瓣狭窄的管理比较

Severe aortic stenosis management in heart valve centres compared with primary/secondary care centres.
PubMed 文献 · Heart · 2023-05-26

IMPULSE enhanced 是一项欧洲前瞻性观察性注册研究,纳入 790 例新诊断重度主动脉瓣狭窄患者,比较心脏瓣膜中心(HVC,4 家)与卫星中心(10 家)的治疗差异。结果显示 HVC 患者基线病情更重、合并症更多,但 3 个月内接受主动脉瓣置换的比例更高(52.6% vs 31.3%),1 年生存率也更高(HR 2.19;95%CI 1.28–3.73)。

要点

  • HVC 患者 3 个月内主动脉瓣置换率高于卫星中心(52.6% vs 31.3%,p<0.001)。
  • 有症状患者中 HVC 的 1 年生存率优于卫星中心(HR 2.89;95%CI 1.64–5.11)。
  • 研究支持建立转诊路径,将重度 AS 患者转至同时开展外科和经导管干预的 HVC。

核心结论

  • HVC 对重度主动脉瓣狭窄患者的干预更及时,1 年生存率更高,支持实施向 HVC 转诊的路径。

研究设计与样本

  • IMPULSE enhanced 为欧洲观察性前瞻性注册研究,纳入 4 家 HVC 和 10 家卫星中心连续新诊断的重度 AS 患者;共 790 例,HVC 组 594 例,卫星组 196 例。

主要发现

  • HVC 患者基线主动脉峰值流速更高(4.3 vs 4.1 m/s;p=0.008),冠心病(44% vs 27%;p<0.001)、既往心肌梗死(11% vs 5.1%;p=0.011)和慢性肺病(17% vs 8.9%;p=0.007)比例更高。
  • 3 个月内主动脉瓣置换率 HVC 组为 52.6%,卫星组为 31.3%(p<0.001);有症状患者中分别为 66.7% 和 43.2%(p<0.001)。
  • 1 年生存率 HVC 组高于卫星组,总人群 HR 2.19(95%CI 1.28–3.73),有症状患者 HR 2.89(95%CI 1.64–5.11)。

临床怎么用

  • 对重度 AS 患者应建立转诊路径,优先转至同时具备外科和经导管主动脉瓣干预能力的 HVC。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Current guidelines recommend use of heart valve centres (HVCs) to deliver optimal quality of care for patients with valve disease but there is no evidence to support this. The hypothesis of this study is that patient care with severe aortic stenosis (AS) will differ in HVCs compared with satellite centres. We aimed to compare the treatment of patients with AS at HVCs (tertiary care hospitals with full access to AS interventions) to satellites (hospitals without such access). METHODS: IMPULSE enhanced is a European, observational, prospective registry enrolling consecutive patients with newly diagnosed severe AS at four HVCs and 10 satellites. Clinical characteristics, interventions performed and outcomes up to 1 year by site-type were examined. RESULTS: Among 790 patients, 594 were recruited in HVCs and 196 in satellites. At baseline, patients in HVCs had more severe valve disease (higher peak aortic velocity (4.3 vs 4.1 m/s; p=0.008)) and greater comorbidity (coronary artery disease (CAD) (44% vs 27%; p<0.001) prior myocardial infarction (MI) (11% vs 5.1%; p=0.011) and chronic pulmonary disease (17% vs 8.9%; p=0.007)) than those presenting in satellites. An aortic valve replacement was performed more often by month 3 in HVCs than satellites in the overall population (52.6% of vs 31.3%; p<0.001) and in symptomatic patients (66.7% vs 43.2%, p<0.001). One-year survival rate was higher for patients in HVCs than satellites (HR2.19; 95% CI 1.28 to 3.73 total population and 2.89 (95%CI 1.64 to 5.11) for symptomatic patients. CONCLUSIONS: Our data support the implementation of referral pathways that direct patients to HVCs performing both surgery and transcatheter interventions. TRIAL REGISTRATION NUMBER: NCT03112629.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Rudolph TK, Messika-Zeitoun D, Frey N, et al. Severe aortic stenosis management in heart valve centres compared with primary/secondary care centres. Heart. 2023. PMID: 36657962. doi:10.1136/heartjnl-2022-321566

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。